[ Back to EurekAlert! ]

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute

Loren Walensky, M.D., Ph.D, Dana-Farber Cancer Institute

Caption: Loren Walensky, M.D., Ph.D, and colleagues have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in relapsed and refractory blood cancers, which are difficult to cure because their cells deploy strong protein "deflector shields" to neutralize the cell death signals that chemotherapy agents used against them initially.

Credit: Sam Ogden

Usage Restrictions: None

Related news release: New drug strategy attacks resistant leukemia and lymphoma


[ Back to EurekAlert! ]